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The Role of Coenzyme Q10 in Statin-Associated Myopathy
A Systematic Review
Leo Marcoff, MD,* Paul D. Thompson, MD†‡
New Haven, Hartford, and Farmington, Connecticut
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are currently the most effective medica-
tions for reducing low-density lipoprotein cholesterol concentrations. Although generally safe, they have been
associated with a variety of myopathic complaints. Statins block production of farnesyl pyrophosphate, an inter-
mediate in the synthesis of ubiquinone or coenzyme Q10 (CoQ10). This fact, plus the role of CoQ10 in mitochon-
drial energy production, has prompted the hypothesis that statin-induced CoQ10 deficiency is involved in the
pathogenesis of statin myopathy. We identified English language articles relating statin treatment and CoQ10
levels via a PubMed search through August 2006. Abstracts were reviewed and articles addressing the relation-
ship between statin treatment and CoQ10 levels were examined in detail. Statin treatment reduces circulating
levels of CoQ10. The effect of statin therapy on intramuscular levels of CoQ10 is not clear, and data on intra-
muscular CoQ10 levels in symptomatic patients with statin-associated myopathy are scarce. Mitochondrial func-
tion may be impaired by statin therapy, and this effect may be exacerbated by exercise. Supplementation can
raise the circulating levels of CoQ10, but data on the effect of CoQ10 supplementation on myopathic symptoms
are scarce and contradictory. We conclude that there is insufficient evidence to prove the etiologic role of CoQ10
deficiency in statin-associated myopathy and that large, well-designed clinical trials are required to address this
issue. The routine use of CoQ10 cannot be recommended in statin-treated patients. Nevertheless, there are no
known risks to this supplement and there is some anecdotal and preliminary trial evidence of its effectiveness.
Consequently, CoQ10 can be tested in patients requiring statin treatment, who develop statin myalgia, and who
cannot be satisfactorily treated with other agents. Some patients may respond, if only via a placebo
effect. (J Am Coll Cardiol 2007;49:2231–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.049C
i
q
m
o
d
p
p
s
f
(
p
C
m
m
e
s
M
E
C
Atatins. Statins or 3-hydroxy-3-methylglutaryl coenzyme
(HMG-CoA) reductase inhibitors competitively inhibit
MG-CoA reductase thereby decreasing synthesis of me-
alonate, a critical intermediary in the cholesterol synthesis
athway (Fig. 1). Their most serious and frequent side
ffects are a variety of myopathic complaints ranging from
ild myalgia to fatal rhabdomyolysis. The incidence of
tatin-associated fatal rhabdomyolysis is only 1.5 deaths per
0 million prescriptions (1). The mechanism of statin
yopathy is unknown, but possible mechanisms include
ecreased sarcolemmal cholesterol (2), reduction in small
uanosine triphosphate-binding proteins (2), increased in-
racellular lipid producing a lipid myopathy (3,4), increased
yocellular phytosterols (5), and mitochondrial dysfunction
ossibly from reduced intramuscular coenzyme Q10
CoQ10) (2,3). The present review examines the evidence
hat CoQ10 is an etiologic factor in statin myopathy.
rom the *Section of Cardiology, Department of Medicine, Yale University School of
edicine, New Haven, Connecticut; †Hartford Hospital, Hartford, Connecticut;
nd the ‡University of Connecticut, Farmington, Connecticut. Dr. Thompson has
eceived research support and speaking honoraria from Merck, Pfizer, AstraZeneca,
chering-Plough, and Kos and owns stock in Merck, Pfizer, and Schering-Plough.T
Manuscript received November 27, 2006; revised manuscript received January 29,
007, accepted February 5, 2007.oQ10. Coenzyme Q10 was discovered by Crane et al. (6)
n 1957. Coenzyme Q10 is a naturally occurring, fat-soluble
uinone that is localized in hydrophobic portions of cellular
embranes. Approximately half of the body’s CoQ10 is
btained through dietary fat ingestion, whereas the remain-
er results from endogenous synthesis (7). Coenzyme Q10
articipates in electron transport during oxidative phos-
horylation in mitochondria, protects against oxidative
tress produced by free radicals (8), and regenerates active
orms of the antioxidants ascorbic acid and tocopherol
vitamin E) (9,10). Statins block production of farnesyl
yrophosphate, an intermediate in the production of
oQ10 (Fig. 1). This fact plus the role of CoQ10 in
itochondrial energy production and the importance of
itochondria in muscle function has prompted the hypoth-
sis that statin-induced CoQ10 deficiency participates in
tatin-associated myopathy.
ethods
nglish language articles relating statin treatment and
oQ10 levels were identified via a PubMed search through
ugust 2006 and from reference citations in other articles.
he PubMed search was performed using various combi-
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Coenzyme Q10 in Statin Myopathy June 12, 2007:2231–7nations of the terms myopathy,
rhabdomyolysis, statin, HMG-
CoA reductase inhibitor, CoQ10,
ubiquinone, and skeletal muscle.
Abstracts were reviewed, and ar-
ticles addressing the relationship
between statin treatment and
CoQ10 levels were examined in
detail.
Effect of Statins on
Circulating CoQ10 Levels
Statins have been known to re-
uce circulating CoQ10 levels in animal models (11) and
umans (12) since at least 1990. Since that time and with
are exceptions (13,14) at least 9 observational studies
12,13,15–23) and 6 randomized controlled trials (7,24–28)
ave demonstrated that statins reduce plasma/serum levels
f CoQ10 16% to 54% (Table 1). The largest trial (25)
ncluded 1,049 patients and noted reductions in plasma
oQ10 levels of 38% and 27% after treatment with atorva-
tatin 10 mg/day to 20 mg/day or lovastatin 20 mg/day to
0 mg/day, respectively. The decrease in blood CoQ10
evels with statin treatment is probably due to reductions in
ower-density lipoproteins. Coenzyme Q10 is transported in
ow-density lipoprotein (LDL) (58  10% of serum
Abbreviations
and Acronyms
CK  creatine kinase
CoQ10  coenzyme Q10
HMG-CoA  3-hydroxy-3-
methylglutaryl coenzyme A
LDL  low-density
lipoprotein
RER  respiratory
exchange ratio
V˙O2 max  maximal oxygen
uptake
Figure 1 Products of Mevalonate Pathway Possibly
Affected by HMG-CoA Reductase Inhibitors (Statins)
Reprinted with permission from Thompson et al. (2). Copyright American Medi-
cal Association ©2003. All rights reserved. HMG-CoA  3-hydroxy-3-methylglu-
taryl coenzyme A.coQ10), high-density lipoprotein (26  8%), and very
ow-density lipoprotein  intermediate-density lipoprotein
16  8%) particles (29). Normalizing CoQ10 concentra-
ions for the reduction in LDL cholesterol or total choles-
erol suggests that there is no change in CoQ10 lipoprotein
article concentration. For example, treatment with simva-
tatin 20 mg/day for 4 weeks (16) reduced serum total
holesterol and CoQ10 levels by 26% and 31%, respectively
p  0.001), but the ratio of serum CoQ10 to total
holesterol decreased only 9% (p  NS). Similar apparently
arallel reductions in total cholesterol have been reported by
t least 7 other authors using a variety of statins (17–19,24–
7) although 2 trials have not found reductions in circulat-
ng CoQ10 levels with statin treatment (14,30).
The hypothesis that a combination of ezetimibe with
imvastatin would counteract the statin-induced decrease in
irculating CoQ10 was tested in a recent trial (20).
zetimibe inhibits intestinal absorption of dietary choles-
erol and increases endogenous cholesterol synthesis.
eventy-two healthy men were randomized to receive either
zetimibe 10 mg/day, simvastatin 40 mg/day, or both for 2
eeks. Ezetimibe alone did not reduce plasma CoQ10
oncentrations (1.1  21%). The combination of simva-
tatin and ezetimibe reduced plasma CoQ10 levels as did
imvastatin alone (28  12% and 16  16%, respec-
ively). The decrease in LDL cholesterol correlated with the
ecrease in plasma CoQ10 levels in all 3 groups (R  0.67,
 0.0001). In addition, the ratios of plasma CoQ10 to
DL cholesterol concentrations were increased in all groups
p  0.0001).
Few studies have examined the effect of statins on
onlipoprotein CoQ10 levels in the circulation, although at
east 1 study (24) reported 12.5% reductions in platelet
oQ10 levels. The mechanism and significance of this
nding are unclear, however, because platelets do not
ontain mitochondria.
ffect of Statins on
keletal Muscle CoQ10 Levels
nimal studies document that statins can reduce ubiqui-
one levels in cardiac muscle and liver (11,31–33). If
oQ10 deficiency contributes, at least in part, to statin-
ssociated myopathy, CoQ10 levels in skeletal muscle
hould also be reduced, but data from animal models are
nconsistent. Whereas simvastatin or pravastatin decreased
keletal muscle ubiquinone up to 72% (p  0.005) when
dministered to rabbits, other studies using rabbits do not
upport these results (34). High-dose statin treatment (50
g/kg of simvastatin or pravastatin per day for 14 days) did
ot reduce skeletal muscle concentrations of ubiquinone in
nimals treated with either drug. Severe lesions in skeletal
uscles developed in the simvastatin-treated rabbits, de-
pite the absence of decreases in muscle ubiquinone levels
32). A recent animal study treated rats with various doses of
erivastatin for 15 days and demonstrated no significant
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biquinone levels in statin-treated animals and nontreated
ontrol animals (35).
In humans, low-dose statin treatment does not appear to
educe intramuscular CoQ10 concentrations (Table 2). In
he first human study to address this issue, skeletal muscle
oQ10 concentrations were actually 47% higher (p  0.001)
fter 4 weeks of treatment with 20 mg of lovastatin daily.
tudies of Blood/Plasma/Serum CoQ10 Levels After Treatment Wi
Table 1 Studies of Blood/Plasma/Serum CoQ10 Levels After T
Study Intervention Du
Folkers et al. (12) Lovastatin, 20–40 mg/day 7–18
Lovastatin, 40 mg/day 29 d
Elmberger et al. (23) (RCT) Pravastatin, 20–40 mg/day 12 w
Watts et al. (15) Simvastatin, 10–80 mg/day 15 
Ghirlanda et al. (7) (RCT) Pravastatin, 20 mg/day 3 m
Simvastatin, 20 mg/day
Bargossi et al. (24) (RCT) Simvastatin, 20 mg/day 3 m
Laaksonen et al. (17) Lovastatin, 20–40 mg/day 12 w
Laaksonen et al. (16) Simvastatin, 20 mg/day 4 w
Laaksonen et al. (18) Simvastatin, 20 mg/day 6 m
De Pinieux et al. (21) Simvastatin/pravastatin/fluvastatin,
doses not reported
Davidson et al. (25) (RCT) Atorvastatin, 10–20 mg/day 1 y
Lovastatin, 20–40 mg/day
Mortensen et al. (26) (RCT) Lovastatin, 20–80 mg/day 18 w
Pravastatin, 10–40 mg/day
Human et al. (22) Simvastatin, 10–20 mg/day 14 w
Miyake et al. (13) Pravastatin, 10–20 mg/day
Simvastatin, 5 mg/day
De Lorgeril et al. (27) (RCT) Simvastatin, 20 mg/day 12 w
Bleske et al. (14) (RCT) Pravastatin, 20 mg/day 4 w
Atorvastatin, 10 mg/day 4 w
Jula et al. (28) (RCT) Simvastatin, 20 mg/day 12 w
Rundek et al. (19) Atorvastatin, 80 mg/day 30 d
Berthold et al. (20) (RCT) Simvastatin, 40 mg/day 2 w
Patients received CoQ10 supplementation before and during treatment with lovastatin; †p  0.0
ormocholesterolemic non–insulin-dependent diabetic patients with or without statin therapy; #com
s either range or mean  SD.
CoQ10  coenzyme Q10; FH  familial hypercholesterolemia; MI  myocardial infarction; NR
tudies of Skeletal Muscle CoQ10 Levels After Treatment With Sta
Table 2 Studies of Skeletal Muscle CoQ10 Levels After Treatm
Study Statin Dosage Duration Participa
Paiva et al. (5) (RCT) Simvastatin, 80 mg/day 8 weeks 48 patients with
hypercholesteAtorvastatin, 40 mg/day
Laaksonen et al. (16) Simvastatin, 20 mg/day 4 weeks 20 patients, age
Laaksonen et al. (18) Simvastatin, 20 mg/day 6 months 19 patients, age
Lamperti et al. (37) Variable NR 18 patients with
myopathy, ag
31–76 yrsp  0.05; †p  0.001.
CI  confidence interval; other abbreviations as in Table 1.Longer treatment, also with simvastatin 20 mg daily,
ielded similar results (18). Coenzyme Q10 levels in muscle
btained from hypercholesterolemic men at baseline and
fter 6 months of statin therapy showed virtually identical
oQ10 concentrations. These values were similar to those
easured in 15 normolipidemic untreated subjects before
nd after 6 months of observation (88 vs. 95 mol/kg,
espectively).
atins
ent With Statins
Participants %Change
hs 5 cardiomyopathic patients, age 43–72 yrs ()51.1–74.6*
1 hypercholesterolemic male volunteer, age 43 yrs ()18.8
12 patients with heterozygous FH, age 19–65 yrs ()29†
ths 20 hyperlipidemic patients, age 55  8.9 yrs ()23.8†‡
10 hypercholesterolemic patients, age 47  8 yrs ()50§
10 hypercholesterolemic patients, age 49  10 yrs ()54§
34 patients with primary hypercholesterolemia, age
not reported
()22.3†
17 men with primary hypercholesterolemia, age
38–65 yrs, 4 weeks after stopping simvastatin
(20–40 mg/day) therapy administered for 4.7 yrs
()25§
22 hypercholesterolemic men, age 25–55 yrs ()32§
19 hypercholesterolemic men, age 25–55 yrs ()27.3
40 hypercholesterolemic patients, age 21–76 yrs ()21†‡
1,049 patients with primary hypercholesterolemia,
age 18–80 yrs
()38†
()27†
45 hypercholesterolemic patients, age 30–75 yrs ()28.8§
()19.7
25 FH patients, age 35.9  11.8 yrs ()25.6
21 non-FH patients, age 52.5  8.94 yrs ()26
97 diabetic patients, age 58.1  10 yrs NS¶
32 patients with primary hypercholesterolemia and
previous Q-wave MI, mean age 54.1 yrs
()19.4§#
12 healthy volunteers, age 26  5 yrs NS
NS
120 hypercholesterolemic men, age 35–64 yrs ()22.0§**
34 hypercholesterolemic patients, age 70  7 yrs ()52§
24 healthy men, age 31.9  8.8 yrs ()16§
mpared to untreated group; §p  0.001; p  0.01; ¶mean serum CoQ10 found to be similar in
to fenofibrate-treated group; **compared to placebo group. Note: age of participants is expressed
eported; NS  not significant; RCT  randomized controlled trial.
ith Statins
[CoQ10]Pre [CoQ10]Post Change (%)
a
39.7  13.6 nmol/g 26.4  7.9 nmol/g () 33.5%*
No reduction No reduction NS
yrs 0.060 mg/g (0.052–0.068)
95% CI
0.088 mg/g (0.083–0.093)
95% CI
() 46.6%†
yrs 78 mol/kg (70–85)
95% CI
85 mol/kg (75–94)
95% CI
NS
29.5 g/g (median in
statin group)
32.0 g/g (median in
control group)
NSth St
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ration
mont
ays
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onths
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eeks
onths
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Coenzyme Q10 in Statin Myopathy June 12, 2007:2231–7The effect of statins on muscle CoQ10 may be drug and
ose dependent. In a recent trial using simvastatin 80
g/day, atorvastatin 40 mg/day, or placebo for 8 weeks (5),
ean muscle concentrations of CoQ10 in the simvastatin-
reated patients decreased by 34%. To date, this is the only
rial comparing intramuscular CoQ10 levels among the
tatins.
There are few published studies on intramuscular CoQ10
evels in subjects symptomatic from statin myopathy. Al-
ost half (47% or 17 of 36 patients) of patients referred for
yopathic complaints presumably due to statin-associated
yopathy had intramuscular CoQ10 levels 2 standard
eviations below the mean (G. Vladitu, personal commu-
ication, August 26, 2005). It is not clear, however, whether
hese decreased intramuscular CoQ10 levels produced statin
yopathy or were simply associated with a reduction in
itochondrial volume associated with the statin myopathy
tself (5) or associated with physical inactivity due to
yopathic symptoms. A recent study (36) examined intra-
uscular CoQ10 levels in patients with statin-associated
yopathy and found levels 2 standard deviations below the
ormal mean in 3 patients, below 1 standard deviation in 7
atients, normal levels in 4 patients, and increased levels in
. No evidence of myocyte apoptosis was found, using
erminal deoxynucleotidyl transferase-mediated deoxyuri-
ine triphosphate nick-end labeling assay and immunohisto-
hemical studies with antibodies against Bax, Bcl-2, and
aspase-3, although only 11 biopsies had enough tissue to
erform the test.
ffect of Statins on Mitochondrial Function
f reduced CoQ10 levels mediate statin myopathy, not only
hould there be evidence of reduced intramuscular CoQ10
evels, but there should also be evidence of impaired
itochondrial function. One animal study (37) showed
ecreased phosphorylation potential of adenosine diphos-
hate in the cardiac mitochondria of guinea pigs treated
ith lovastatin 20 mg/kg twice daily. This correlated with a
7% and 31% decrease in CoQ10 concentration in cardiac
itochondria and myocardium, respectively. Curiously,
hese changes were observed in the older animals (2 years
ld), but not younger ones (2 to 4 months old), suggesting
possible age effect. Similarly, myocardium of dogs treated
ith simvastatin 2 mg/kg/day for 3 weeks contained lower
oncentrations of CoQ10 and decreased mitochondrial
espiration during ischemia induced by left anterior de-
cending coronary artery ligation, compared with untreated
ontrol patients or a pravastatin-treated group (38). In rats,
ravastatin reduced mitochondrial complex I activity in the
iaphragm and psoas major muscles in 35- to 55-week-old
nimals and decreased complex IV activity in 55-week-old
nimals (39). Various doses of cerivastatin (0.1, 0.5, or 1.0
g/kg/day for 15 days) administered to rats did not produce
orphologic abnormalities in skeletal muscle after 10 daysf statin treatment (35). At 15 days, inflammation and aecrosis with structurally altered mitochondria involving
ype II myofibers was observed in the mid/high dose groups.
owever, mitochondria in the unaffected adjacent myocytes
ppeared normal, prompting the authors to conclude that
itochondrial damage did not precede myofiber degenera-
ion. No significant changes in mitochondrial function were
bserved, and mitochondrial function did not correlate with
hanges in ubiquinone concentration. This study supports
n earlier trial in rats (40) in which simvastatin treatment
id not result in a significant change in ATP production in
uscle, heart, liver, or brain, despite lower blood ATP
evels.
Few studies have directly or indirectly addressed this issue
n humans. de Pinieux et al. (21) examined the ratio of
erum lactate to pyruvate as an indirect measure of mito-
hondrial function. Statin-treated hypercholesterolemic pa-
ients had 16% higher fasting, nonexercise, lactate:pyruvate
atios than untreated hypercholesterolemic patients (p 
.05). In contrast mean lactate:pyruvate ratios with fibrates
ere not significantly higher than those of the untreated
yperlipidemic patients. Curiously, regardless of statin,
brate, or no treatment, mean lactate:pyruvate ratios were
igher in the hypercholesterolemic patients than in the
ormocholesterolemic control patients.
Others have also suggested that mitochondrial function
ay be impaired by statin therapy. Muscle biopsies from 4
atients with statin-associated myopathy, despite normal
reatine kinase (CK) levels, demonstrated findings consis-
ent with mitochondrial dysfunction, including increased
ntramuscular lipid, diminished cytochrome oxidase stain-
ng, and ragged red fibers (3). Three of these patients had
epeat biopsies performed after discontinuation of statin,
hich showed resolution of the pathologic abnormalities.
hese same investigators used respiratory exchange ratios
RER V˙CO2/V˙O2) during exercise as a measure of exercise
erobic metabolism and an indirect measure of mitochon-
rial function (41). Sixteen healthy subjects received ator-
astatin 5 to 10 mg for 6 weeks. Exercise results in these
ubjects were compared with those from 9 men and 2
omen who developed muscle complaints plus CK eleva-
ions during statin alone (n  6), statin and fibrate (n  3),
r statin and niacin (n  2) therapy. There was no effect of
tatin therapy on maximal oxygen uptake (V˙O2 max), a
easure of aerobic fitness, in the normal patients, but V˙O2
ax was significantly lower in the myopathic patients, a
nding the authors attributed to these patients’ physical
nactivity due to their myopathy. Interestingly, the resting
ER increased with statin therapy in the normal subjects
0.75  0.02 to 0.86  0.06), and was also elevated in the
yopathic patients off statin therapy (0.90  0.07). Respi-
atory exchange ratio decreases with fat oxidation and
ncreases as carbohydrate is used as fuel, but is a crude
easure of these processes. The authors interpreted their
ndings as demonstrating that statins impair fat metabolism
n healthy patients and that victims of statin myopathy have
pretreatment abnormality in fat metabolism that is exac-
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June 12, 2007:2231–7 Coenzyme Q10 in Statin Myopathyrbated by statin therapy leading to the muscle complaints.
here was no apparent change in the onset of lactate
ccumulation or “anaerobic threshold” during the exercise
est, however, which argues against an alteration in exercise
at metabolism with statin treatment. One additional study
f 195 noninsulin diabetic patients noted a 6% increase in
esting RER (0.78 to 0.83), which the authors attributed to
mproved glucose metabolism with statin treatment, but
xercise parameters were not measured in that study (42).
onsequently, these exercise results raise the possibility of
itochondrial dysfunction during exercise, a problem that
ould relate to CoQ10 depletion.
In contrast to these studies suggesting a mitochondrial
roblem in statin myopathy (13,21–23,41–48), muscle biop-
ies from 18 patients with statin-associated myopathy found
nly 2 patients with decreased intramuscular levels of CoQ10
nd some morphologic evidence of mitochondrial dysfunction
36). Muscle biopsies from these patients revealed the
resence of a few ragged red fibers or cytochrome c
xidase-negative fibers. It is not clear whether these
hanges were produced by the depletion of CoQ10 or were
elated to aging, given that both patients were older than 60
ears old. In addition, the activity of complex III of the
itochondrial respiratory chain, which is dependent on
oQ10 activity, was normal in all participants.
Others have directly measured concentrations of high
nergy phosphates, including adenosine triphosphate and
reatine phosphate, in the skeletal muscle of statin-treated
atients and found no changes despite 6 months of treat-
ent with 20 mg/day of simvastatin, suggesting that energy
upply to the muscle was not compromised (18). These
tudies were performed at rest, however, and more subtle
ifferences may be obvious with exercise or during exercise
ecovery.
oQ10 Supplementation
number of studies (12,13,24,30) have demonstrated that
oQ10 administration can increase CoQ10 blood levels in
atients treated with statins. Coenzyme Q10 supplementa-
ion may also reduce the symptoms of statin-induced
yopathy in patients treated with massive statin doses
43,44). Lovastatin was investigated as a potential cancer
reatment in doses up to 45 mg/kg body weight. Among 56
ancer patients treated with monthly 7-day courses of
igh-dose (2 mg/kg/day to 45 mg/kg/day) lovastatin, over
he course of 2 and a half years, CoQ10 supplementation
240 mg/day) did not reduce the frequency of lovastatin-
nduced myopathy compared with that in unsupplemented
atients, but did decrease the severity of myopathic symp-
oms, judged by a grading scale that included duration of
yalgia and degree of CK elevations. Interestingly, patients
eceiving lovastatin at doses25 mg/kg/day did not develop
usculoskeletal toxicity, and at higher doses there was no
orrelation between the incidence of myotoxicity and the
ose of lovastatin (p 0.24) (43). Another trial (44) treated s6 patients with advanced gastric adenocarcinoma with
ovastatin 35 mg/kg/day for 7 consecutive days. All subjects
eceived 240 mg of CoQ10 daily. Only 2 patients developed
ncreased CK levels, myalgia, and muscle weakness. The
uthors reported that symptoms were successfully managed
ith CoQ10 and symptomatic treatment. The dose of
oQ10 required for this treatment was not specified nor
as a control group without supplementation included.
There are only 2 randomized trials, both in abstract form,
hat were designed to evaluate CoQ10 as a treatment for
tatin-associated myopathy (45,46). The first treated 41
atients with statin-associated myalgia with either 400 IU
f vitamin E or 100 mg of CoQ10 daily for 30 days.
reliminary results suggest a significant improvement in
ain scores in patients treated with CoQ10, with 18 of 21
eporting improvement in symptom severity and a reduction
n mean pain scores (6.2 1.7 to 3.1 2.2 at baseline using
10-point scale (p  0.001). By comparison, only 3 of 20
atients on vitamin E reported improvement in their symp-
oms, and there was no change in this group’s mean pain
core (3.9  2.2 vs. 3.1  2.2, p  NS). These results
equire confirmation.
A more recent trial (46) randomized 44 dyslipidemic
atients with prior statin-induced myalgia to 12 weeks of
reatment with escalating doses of simvastatin (10 mg/day
o 40 mg/day) and CoQ10 200 mg/day or placebo. Plasma
oQ10 levels increased with CoQ10 supplementation, but
here were no differences in myalgia scores (p  0.63) or in
tatin tolerance between the 2 treatment groups. Specifi-
ally, similar numbers of patients in both groups were able
o tolerate simvastatin 40 mg (p  0.34) and 10 mg (p 
.35) daily.
onclusions and Clinical Implications
tatins are the most effective medications for reducing LDL
holesterol concentrations. They have been proven to de-
rease the incidence of adverse cardiac events in diverse
atient populations. The primary adverse effect limiting
heir use is myopathy, ranging from benign myalgias to rare
ases of fatal rhabdomyolysis. Statins’ interference with the
roduction of CoQ10 prompted the hypothesis that CoQ10
eficiency may play a role in statin-associated myopathy.
lthough statins reduce circulating levels of CoQ10, this
ffect is nullified by normalizing CoQ10 concentrations for
he reduction in LDL cholesterol or total cholesterol.
ow-dose statin treatment does not appear to reduce
ntramuscular levels of CoQ10 in humans. Few data are
vailable regarding intramuscular CoQ10 levels in symp-
omatic patients with statin-associated myopathy. Mito-
hondrial function may be impaired by statin therapy, and
his effect may be exacerbated by exercise, but confirmatory
ata are needed. Animal models of statin myopathy dem-
nstrate similar results in that decreases in skeletal muscle
biquinone levels and mitochondrial function are not con-
istent and skeletal muscle injury can occur without de-
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Coenzyme Q10 in Statin Myopathy June 12, 2007:2231–7reases in muscle CoQ10 concentrations. Supplementation
an raise the circulating levels of CoQ10, but whether or not
his relieves myopathic symptoms is not clear. The 2
vailable double-blind studies report contrasting results and
re only available in abstract form. Presently, insufficient
vidence exists to implicate CoQ10 deficiency as the cause
f statin-associated myopathy. Our evaluation of this data is
hat intramuscular CoQ10 depletion does not cause statin
yopathy and that CoQ10 supplementation does not mit-
gate the symptoms of statin myopathy. Nevertheless, there
re no known risks to this supplement. Also, reports from
ancer trials using high-dose statins (44,45), results from 1
f the 2 available clinical trials (45,46), and clinical anec-
otes suggest that some patients benefit from CoQ10
upplementation. This variable response could be explained
y a placebo effect or by genetic and other variability among
atients. For example, there are at least 2 reported cases of
itochondrial encephalopathy lactic acidosis and stroke-like
pisodes temporally related to statin therapy that appeared
o benefit from CoQ10 therapy (47,48). Consequently,
lthough there is no definite evidence of its effectiveness,
oQ10 supplementation, 200 mg daily, can be trialed in
atients requiring statin treatment, who develop statin
yalgia, and who cannot be satisfactorily treated with other
gents. Some patients may respond if only via a placebo
ffect.
uture Directions
tatin therapy is frequently limited by myopathic symptoms
reating a critical need for strategies to prevent statin
yopathy. Coenzyme Q10 supplementation is a simple,
ttractive therapy that requires an appropriately powered
nd randomized trial to determine whether CoQ10 elimi-
ates or reduces statin myalgia in symptomatic patients.
imultaneous genetic studies should attempt to determine if
enetic variants contribute to the variability in the response
o CoQ10 therapy. Studies designed to determine if CoQ10
revents the onset of myalgia in statin-naive patients are not
ractical because of the number of subjects that would be
equired in such a trial. In addition, the absence of phar-
acologic grade CoQ10 supplement and a study sponsor
akes such a trial difficult. Nevertheless, such trials are the
nly way to demonstrate conclusively whether or not clini-
ians should prescribe CoQ10 to their patients on statin
herapy.
eprint requests and correspondence: Dr. Paul D. Thompson,
ardiology, Hartford Hospital, 80 Seymour Street, Hartford,
onnecticut 06102. E-mail: pthomps@harthosp.org.
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